BUX — BioMark Diagnostics Share Price
Last trade - 00:00- CA$36.78m
- CA$37.24m
- CA$0.16m
- 13
- 12
- 62
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 237.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -1259.72% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.26 | n/a | 0.04 | 0.15 | 0.16 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioMark Diagnostics Inc. is a developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The Company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. It is also engaged in developing accessible diagnostic solutions to address unmet medical needs in oncology. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. Its oncology has developed a liquid biopsy metabolic panel assay, which is instrumental for early-stage diagnosis of lung cancer.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 19th, 2014
- Public Since
- November 3rd, 2014
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 105,090,213
- Address
- 130 3851 Shell Road, RICHMOND, V6X 2W2
- Web
- https://www.biomarkdiagnostics.com/
- Phone
- +1 6048366950
- Auditors
- MNP LLP
Upcoming Events for BUX
Similar to BUX
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
BetterLife Pharma
Canadian Securities Exchange
Biovaxys Technology
Canadian Securities Exchange
FAQ
As of Today at 19:36 UTC, shares in BioMark Diagnostics are trading at CA$0.35. This share price information is delayed by 15 minutes.
Shares in BioMark Diagnostics last closed at CA$0.35 and the price had moved by +45.83% over the past 365 days. In terms of relative price strength the BioMark Diagnostics share price has outperformed the Toronto Stock Exchange 300 Composite Index by +18.99% over the past year.
There is no consensus recommendation for this security.
Find out moreBioMark Diagnostics does not currently pay a dividend.
BioMark Diagnostics does not currently pay a dividend.
BioMark Diagnostics does not currently pay a dividend.
To buy shares in BioMark Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.35, shares in BioMark Diagnostics had a market capitalisation of CA$36.78m.
Here are the trading details for BioMark Diagnostics:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: BUX
Based on an overall assessment of its quality, value and momentum BioMark Diagnostics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioMark Diagnostics. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +61.82%.
As of the last closing price of CA$0.35, shares in BioMark Diagnostics were trading +35.42% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BioMark Diagnostics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on BioMark Diagnostics' directors